{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:52:34Z","timestamp":1790855554568,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejmech.2023.115349","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T02:14:12Z","timestamp":1681179252000},"page":"115349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Discovery of novel sulfonamide chromone-oxime derivatives as potent indoleamine 2,3-dioxygenase 1 inhibitors"],"prefix":"10.1016","volume":"254","author":[{"given":"Ke","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Hao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Ling","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Na","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri-Zhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115349_bib1","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2023.115349_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115349_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115349_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd4596","article-title":"Big opportunities for small molecules in immuno-oncology","volume":"14","author":"Adams","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115349_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trecan.2017.11.005","article-title":"Inflammatory reprogramming with Ido1 inhibitors: turning immunologically unresponsive \u2018cold\u2019 tumors \u2018hot\u2019","volume":"4","author":"Prendergast","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2023.115349_bib6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ejmech.2017.11.088","article-title":"Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy","volume":"143","author":"Weng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115349_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1432-2277.2004.00031.x","article-title":"Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo","volume":"18","author":"Bauer","year":"2005","journal-title":"Transpl. Int."},{"key":"10.1016\/j.ejmech.2023.115349_bib9","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.1021\/jm401195n","article-title":"Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in lewis lung cancer (LLC) tumor-bearing mice","volume":"56","author":"Yang","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115349_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111750","article-title":"Effective virtual screening strategy toward heme-containing proteins: identification of novel Ido1 inhibitors","volume":"184","author":"Zou","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib12","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115349_bib13","doi-asserted-by":"crossref","first-page":"9760","DOI":"10.1021\/acs.jmedchem.6b00718","article-title":"New inhibitors of indoleamine 2,3-dioxygenase 1: molecular modeling studies, synthesis, and biological evaluation","volume":"59","author":"Coluccia","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pharmthera.2018.12.004","article-title":"Targeting indoleamine-2,3-dioxygenase in cancer: scientific rationale and clinical evidence","volume":"196","author":"Ricciuti","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115349_bib15","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1021\/acs.jmedchem.5b00326","article-title":"Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (Ido1) inhibitors","volume":"58","author":"Rohrig","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113071","article-title":"Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors","volume":"211","author":"Singh","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (Ido1) inhibitor for immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115349_bib18","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1021\/acs.jmedchem.7b00974","article-title":"Discovery of a novel and selective indoleamine 2,3-dioxygenase (Ido-1) inhibitor 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271\/PF-06840003) and its characterization as a potential clinical candidate","volume":"60","author":"Crosignani","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib19","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1021\/acs.jmedchem.9b00662","article-title":"Discovery of clinical candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyc lohexan-1-ol (navoximod), a potent and selective inhibitor of indoleamine 2,3-dioxygenase 1","volume":"62","author":"Kumar","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2023.115349_bib21","doi-asserted-by":"crossref","first-page":"TPS4587","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4587","article-title":"A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) \u00b1 BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC)","volume":"37","author":"Sonpavde","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115349_bib22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2019.37.7_suppl.358","article-title":"BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (Ido1), in combination with nivolumab (nivo): updated safety across all tumor cohorts and efficacy in advanced bladder cancer (AdvBC)","volume":"37","author":"Luke","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115349_bib23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1107\/S2053230X18012955","article-title":"High-resolution structures of inhibitor complexes of human indoleamine 2,3-dioxygenase 1 in a new crystal form","volume":"74","author":"Luo","year":"2018","journal-title":"Acta Crystallogr. F"},{"key":"10.1016\/j.ejmech.2023.115349_bib24","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acs.jmedchem.9b01386","article-title":"Bifunctional naphthoquinone aromatic amide-oxime derivatives exert combined immunotherapeutic and antitumor effects through simultaneous targeting of indoleamine-2,3-dioxygenase and signal transducer and activator of transcription 3","volume":"63","author":"Huang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib25","doi-asserted-by":"crossref","first-page":"15749","DOI":"10.1021\/acs.jmedchem.2c01320","article-title":"Identification of a novel potent CYP4Z1 inhibitor attenuating the stemness of breast cancer cells through lead optimization","volume":"65","author":"Yuan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib26","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1016\/j.bmcl.2014.05.084","article-title":"Discovery and structure\u2013activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors, Bioorg, Med","volume":"24","author":"Cheng","year":"2014","journal-title":"Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115349_bib27","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1021\/cr400265z","article-title":"Chromone: a valid scaffold in medicinal chemistry","volume":"114","author":"Gaspar","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2023.115349_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcp.2019.07.011","article-title":"Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting Ido1\/Ido2\/TDO","volume":"168","author":"Feng","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115349_bib29","first-page":"3780","article-title":"Identification and preliminary structure\u2013activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors, Bioorg","volume":"25","author":"Gao","year":"2017","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113631","article-title":"Design, synthesis and biological evaluation of exiguamine A analogues as Ido1 inhibitors","volume":"223","author":"Dong","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib31","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1021\/acs.jmedchem.0c01968","article-title":"Azole-based indoleamine 2,3-dioxygenase 1 (Ido1) inhibitors","volume":"64","author":"Rohrig","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib32","doi-asserted-by":"crossref","first-page":"7364","DOI":"10.1021\/jm900518f","article-title":"Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model","volume":"52","author":"Yue","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112067","article-title":"Synthesis, mechanisms of action, and toxicity of novel aminophosphonates derivatives conjugated irinotecan in vitro and in vivo as potent antitumor agents","volume":"189","author":"Huang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112951","article-title":"Design, synthesis and antitumor evaluation of new 1,8-naphthalimide derivatives targeting nuclear DNA","volume":"210","author":"Liang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115349_bib35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcp.2019.07.011","article-title":"Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting Ido1\/Ido2\/TDO","volume":"168","author":"Feng","year":"2019","journal-title":"Biochem. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342300315X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342300315X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:50:57Z","timestamp":1759330257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342300315X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":35,"alternative-id":["S022352342300315X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115349","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel sulfonamide chromone-oxime derivatives as potent indoleamine 2,3-dioxygenase 1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115349"}}